Mergers & acquisitions
Nevada-based PDL BioPharma, Inc. said it will no longer pursue a proposed acquisition of Neos Therapeutics.
Novartis may soon be looking to sell off its generics subsidiary Sandoz.
Roche will plunk down $1.9M to acquire Flatiron Health, which has previously been backed by GV, as well as Roche.
Investors and analysts had been encouraging Gilead to acquire something for a long time, so they were mostly happy when it bought Kite Pharma in September.
Hayao will also form a JV with GNC to make and distribute GNC supplements in China.
The acquisition will strengthen Charles River’s position as a global early-stage CRO, expanding its client base and service portfolio.
According to sources reported by Reuters, potential buyers have been winnowed down to two pharma companies, three private equity funds, and a consortium of buyers.
Companies including Sanofi, J&J, Nestle have dropped out.
Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements.
NCPC GeneTech, the biotech division of North China Pharma, in-licensed China rights for a biosimilar to a second-gen renal anemia treatment from South Korea’s CJ Healthcare.
PRESS RELEASES